Equitable Care of Metastatic Breast Cancer Patients
Conquer Cancer, the ASCO Foundation, and Pfizer Global Medical Grants are collaborating to offer a research grant funding opportunity to promote the advancement of scientific knowledge concerning equitable care of metastatic breast cancer (mBC) patients. This research grant program will employ data-driven frameworks to define and address inequities in the delivery of care and outcomes for patients of color with metastatic breast cancer. This program is aligned with the theme of the 2021 ASCO Annual Meeting; Equity: Every Patient. Every Day. Everywhere.
Conquer Cancer is the lead organization for the review and evaluation of applications. Grant funding will be provided directly from Pfizer.
Successful applicants to this RFP will be expected to share the initial results of their research at a future grantee meeting to be convened by Conquer Cancer in late 2022. They will also be invited to submit applications to an anticipated Pfizer-funded RFP in early 2023 to implement any of the potential solutions to the care disparities uncovered during the initial project term.
Areas of Interest
The research areas of interest for this RFP are:
Understanding racial disparities in the access to and delivery of treatment and supportive care, including psychosocial and palliative care, for patients with metastatic breast cancer.
Understanding racial disparities in the outcomes for patients with metastatic breast cancer.
Systematic analyses of disparities within care delivery systems and communities.
The overall aim is to identify disparities in delivery of care and treatment outcomes for patients of color with metastatic breast cancer, based on a specific understanding of the variables that may be related to the inequity. Variables can include socioeconomic factors, as well as other variables as identified through research, of a given care delivery system and the communities served by the system. Studies supported by this program should support models to facilitate similar analyses aimed at identifying inequities in other health care systems.
Collectively, up to $1.5 million USD is available to fund approximately 10 research projects under this RFP. Individual projects requesting up to $150,000 over one year will be considered.
The institution and principal investigator (PI) must be based in the United States.
Eligible institutions include Academic Cancer Centers, Healthcare Delivery Networks, and large Community Cancer Centers or Hospitals.
Only organizations are eligible to receive grants, not individuals or physician-owned medical group practices.
The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy, Physiotherapy, or Social Work.
The principal investigator (PI) must be affiliated with the applicant institution.
The full application must be submitted in accordance with the requirements and instructions of the Request for Proposals (RFP) by the application deadline. A Letter of Intent (LOI) is not required. All application materials must be in English and must be submitted through the Application Portal. Paper applications or applications sent by e-mail or fax will not be accepted. If you have questions, please email our Grants team.
- Application Deadline: August 4, 2021, 11:59 PM ET
- Anticipated Notification of Award: November 1, 2021
- Anticipated Grant Term: January 1, 2022 – December 31, 2022
Grant funding will be provided directly from Pfizer.